Quick Answer
– The Ozempic litigation is a federal mass tort consolidated under MDL 3094 in the Eastern District of Pennsylvania, not a traditional class action.
– Claimants who suffered gastroparesis, intestinal obstruction, or related GLP-1 injuries after taking Ozempic or Wegovy may qualify to file.
– Estimated settlement amounts range from $100,000 to $1.5 million or more, depending on injury severity, hospitalization history, and medical documentation.
Case Snapshot
| Detail | Info |
|---|---|
| Court | U.S. District Court, Eastern District of Pennsylvania |
| MDL Number | MDL 3094 |
| Case Caption | In re: Ozempic (Semaglutide) Products Liability Litigation |
| Presiding Judge | Chief Judge Chad F. Kenney |
| MDL Transfer Order | December 14, 2023 |
| Status (2026) | Active pretrial proceedings; bellwether trials scheduled |
| Defendants | Novo Nordisk Inc., Novo Nordisk A/S |
| Claimants in MDL | 12,000+ federal cases as of early 2026 (figure growing) |
| Primary Legal Theory | Failure to warn; product liability |
| FDA Label Action | August 2023, gastroparesis added to adverse event documentation |
The Ozempic lawsuit settlement amounts question has no single answer. What it has is a structure. Under MDL 3094, cases are grouped by injury severity and moving toward bellwether trials that will set the market for all individual settlements.
Tens of thousands of patients who took Ozempic, Wegovy, or related semaglutide drugs for diabetes or weight loss are now claiming the drugs caused gastroparesis, intestinal obstruction, and other severe gastrointestinal disorders. Novo Nordisk knew or should have known about these risks before adequate warnings appeared on labels, according to plaintiffs' filings.
The scale of this litigation is significant. By early 2026, MDL 3094 carries over 12,000 federal cases. That volume, combined with ongoing bellwether scheduling, makes 2026 a decisive year for claimant strategy.
Understanding where individual case values land requires knowing the injury tier system, the trial schedule, and the defendant's litigation posture. Each of those factors shapes real dollars.
Ozempic Lawsuit Settlement Amounts: What the Numbers Look Like in 2026
Ozempic lawsuit settlement amounts in 2026 have not yet been finalized through a global settlement fund, but bellwether trial results and early individual resolutions provide a working framework for case valuation.
Based on comparable pharmaceutical mass torts and the injury categories present in MDL 3094, attorneys handling these claims project compensation in the following ranges:
| Injury Severity | Estimated Settlement Range |
|---|---|
| Mild-moderate gastroparesis, no surgery | $75,000 to $200,000 |
| Severe gastroparesis, hospitalization required | $200,000 to $500,000 |
| Intestinal obstruction requiring surgery | $400,000 to $900,000 |
| Permanent gastric injury or feeding tube dependency | $700,000 to $1.5 million |
| Wrongful death claims | $1 million to $3 million+ |
These are projected ranges, not confirmed settlement payments. No global resolution has been announced as of early 2026.
*Attorneys handling these claims point to the Vioxx and Invokana mass torts as reference points, where bellwether verdicts directly anchored final compensation grids before any fund was formalized.*
Bold callout: The absence of a global settlement fund does not mean claimants are waiting indefinitely. Early individual resolutions within MDL proceedings occur regularly before any master settlement agreement is signed.
Ozempic Lawsuit Average Settlement Amount: How Case Value Is Calculated
The ozempic lawsuit average settlement amount depends on a specific set of damages categories that mass tort attorneys assess at intake.
No single average applies uniformly. A claimant who was hospitalized twice for gastroparesis and required a gastric pacemaker implant carries a very different case value than one who experienced prolonged nausea and missed work for two months.
The core damages categories for each case are:
- Medical expenses: All documented costs, past and projected future care
- Lost wages and earning capacity: Verified income loss tied to the injury period
- Pain and suffering: Calculated as a multiplier of economic damages in most jurisdictions
- Loss of consortium: Recognized in most states for spouses of severely injured claimants
- Punitive damages: Possible if plaintiffs establish Novo Nordisk had internal knowledge of risks and concealed them
*Attorneys handling these claims point to internal corporate communications and clinical trial data as the strongest levers for punitive damage arguments.*
Litigation Watch: Settlement amounts are not random. They follow a damages grid shaped by hospitalization records, surgical history, and whether the manufacturer's internal documents show prior knowledge of the risk.
Ozempic Lawsuit Payout Per Person: Individual vs. Global Resolution
The ozempic lawsuit payout per person depends heavily on whether the litigation resolves through individual negotiations or a master settlement agreement covering all MDL claimants.
In a global resolution, defendants typically negotiate a total fund. A claims administrator then assigns each claimant a tier and point value based on injury documentation. Final individual checks are cut from that pool.
In individual resolutions, which happen before any master agreement, attorneys negotiate directly with Novo Nordisk's defense counsel. Those cases often resolve at higher per-person values because there is no averaging effect across a large claimant pool.
| Resolution Type | How Payout Is Determined | Timing |
|---|---|---|
| Individual pretrial settlement | Direct negotiation, case-by-case | Can happen before global resolution |
| Global settlement fund | Injury tier and point system | After bellwether trials conclude |
| Verdict after trial | Jury award minus appeals process | Longest timeline |
*Attorneys handling these claims point to the importance of complete medical record submission early, because documentation quality directly affects tier placement under any fund formula.*
How Much Can You Get From the Ozempic Lawsuit: Realistic Expectations
How much you can get from the Ozempic lawsuit depends on four primary factors that courts and defendants weigh consistently in pharmaceutical mass torts.
First is injury severity and duration. A claimant who spent three weeks hospitalized with aspiration pneumonia caused by gastroparesis has a documentably different case than one who self-managed symptoms at home.
Second is causation documentation. Plaintiffs must show they took a qualifying GLP-1 drug, suffered a qualifying injury, and that the injury is medically linked to the drug's effect on gastric motility. The clearer that chain, the stronger the case.
Third is whether the claimant received adequate warning. Patients who began taking Ozempic before the FDA's August 2023 adverse event documentation update have a stronger failure-to-warn argument.
Fourth is the defendant's financial exposure posture as trial approaches.
Key factors affecting individual payout:
- Date of Ozempic/Wegovy use relative to FDA label update
- Number of hospitalizations and total medical spend
- Whether surgery was required
- Whether permanent disability resulted
- Quality and completeness of medical records submitted
- State law governing damages caps, if applicable
*Attorneys handling these claims point out that claimants who took the drug before August 2023 generally carry stronger pre-warning failure-to-warn arguments.*
Ozempic Lawsuit Compensation Tiers: How Mass Tort Funds Assign Value
Ozempic lawsuit compensation tiers are the structured categories a claims administrator uses to assign individual payout amounts once a global settlement fund is established.
Tier systems are standard in large pharmaceutical mass torts. The Roundup litigation used a tier framework. The 3M earplugs MDL employed a point-based system. MDL 3094 has not yet published a formal tier grid, but the injury categories present in the litigation already suggest the likely structure.
Based on MDL 3094 plaintiff filings and the injury spectrum in the case, a working tier model looks like this:
| Tier | Qualifying Condition | Estimated Compensation Range |
|---|---|---|
| Tier 1 | Documented gastroparesis, no hospitalization | $75,000 to $150,000 |
| Tier 2 | Gastroparesis with one or more hospitalizations | $200,000 to $450,000 |
| Tier 3 | Intestinal obstruction or ileus requiring procedure | $400,000 to $800,000 |
| Tier 4 | Surgical intervention, permanent impairment | $700,000 to $1.5 million |
| Tier 5 | Wrongful death | $1 million to $3 million+ |
These are projected tiers drawn from case filings and comparable litigation history. The official fund formula will be negotiated between the Plaintiff Steering Committee and Novo Nordisk's counsel.
*Attorneys handling these claims point to the importance of injury documentation that clearly maps to one of the upper tiers, as ambiguous records tend to result in tier-down placement.*
Litigation Watch: The absence of a formal tier grid in 2026 is not a procedural delay. It reflects the fact that bellwether trials must first establish what juries are willing to award before defendants will negotiate a global fund formula.
Ozempic Lawsuit Who Qualifies: The Eligibility Requirements
Ozempic lawsuit eligibility requires meeting a specific set of factual criteria that plaintiffs' attorneys screen for at intake.
Not every person who took Ozempic and experienced nausea qualifies. The litigation targets serious, documented gastrointestinal injuries that required medical intervention.
Eligibility criteria, as reflected in MDL 3094 plaintiff filings:
- Prescribed and used Ozempic, Wegovy, Rybelsus, or another semaglutide-based drug
- Used the drug for at least 30 days (general threshold used by intake counsel)
- Diagnosed with gastroparesis, gastric motility disorder, intestinal obstruction, ileus, or a related condition
- Diagnosis made by a physician and documented in medical records
- Injury required hospitalization, procedure, or ongoing medical treatment
- No pre-existing diagnosis of gastroparesis before drug use began
Potentially qualifying products:
- Ozempic (semaglutide injection, Novo Nordisk)
- Wegovy (higher-dose semaglutide, Novo Nordisk)
- Rybelsus (oral semaglutide, Novo Nordisk)
- Mounjaro (tirzepatide, Eli Lilly) — parallel litigation, separate proceedings
*Attorneys handling these claims point to pre-existing condition review as the first filter, since Novo Nordisk's defense strategy centers on arguing the claimant's injury predates drug use.*
Ozempic Lawsuit Injuries That Qualify: The Medical Conditions at the Center of This Case
The injuries that qualify for the Ozempic lawsuit are gastrointestinal conditions with documented links to GLP-1 receptor agonist use.
GLP-1 drugs slow gastric emptying. That mechanism, intended to help manage blood sugar and promote satiety, can cause the stomach's muscular contractions to weaken significantly. In vulnerable patients, the result is clinical gastroparesis or more severe obstructive conditions.
Qualifying injuries in MDL 3094:
- Gastroparesis: Delayed gastric emptying confirmed by gastric emptying study
- Gastric motility disorder: Broader diagnostic category including partial gastroparesis
- Intestinal obstruction / bowel obstruction: Blockage requiring emergency intervention
- Ileus: Temporary cessation of bowel movement following drug use
- Aspiration pneumonia: Caused by regurgitation secondary to gastroparesis
- Bezoar formation: Hardened mass in stomach from undigested food accumulating
- Severe dehydration and malnutrition: Secondary to persistent vomiting from gastroparesis
*Attorneys handling these claims point to gastric emptying studies and hospital discharge summaries as the two most important pieces of medical documentation for any qualifying injury.*
Bold callout: Nausea or vomiting alone, without an underlying diagnosis, is unlikely to meet the injury threshold for MDL 3094 case acceptance.
Ozempic Gastroparesis Lawsuit Settlement: The Core Injury in This Litigation
The Ozempic gastroparesis lawsuit is the dominant category within MDL 3094, representing the largest share of filed claims.
Gastroparesis means the stomach cannot empty itself normally. Patients experience chronic nausea, vomiting, bloating, and, in severe cases, inability to eat solid food. The condition can be permanent. For plaintiffs who developed it after starting Ozempic, the legal argument centers on whether Novo Nordisk warned prescribers and patients adequately.
The FDA's August 2023 update to semaglutide labeling added gastroparesis to adverse event documentation. For patients who began using Ozempic years before 2023, that timing is legally significant. It supports the argument that the manufacturer had sufficient data to warn earlier but did not.
| Gastroparesis Severity | Documented Medical Requirement | Estimated Settlement Range |
|---|---|---|
| Mild, resolved without hospitalization | Physician diagnosis, medication records | $75,000 to $175,000 |
| Moderate, one or more hospital stays | Discharge summaries, gastric emptying study | $200,000 to $400,000 |
| Severe, feeding tube or gastric pacemaker | Surgical records, specialist documentation | $600,000 to $1.5 million |
*Attorneys handling these claims point to the August 2023 FDA label update as a double-edged issue: it strengthens pre-2023 failure-to-warn claims while potentially weakening claims from patients who began treatment after adequate warnings were in place.*
Litigation Watch: Gastroparesis severity and the date of first Ozempic use relative to the FDA's 2023 label action are the two variables that most sharply distinguish high-value from moderate-value claims in MDL 3094.
Ozempic Lawsuit Intestinal Obstruction: A Distinct and Severe Injury Category
Ozempic-linked intestinal obstruction claims represent a separate and generally higher-value category within the MDL 3094 litigation.
Intestinal obstruction means a blockage in the small or large intestine that prevents normal passage of food and waste. Unlike gastroparesis, which affects stomach motility, obstruction can become a surgical emergency within hours. Patients have required bowel resections. Some have died from complications.
These cases attract attention from defense counsel precisely because juries respond strongly to surgical emergencies and documented near-death outcomes.
What distinguishes intestinal obstruction claims:
- Emergency room presentation with imaging confirmation
- Surgical intervention records (resection, colostomy, stenting)
- ICU admission history
- Long-term dietary restriction or colostomy dependence
- Documented connection between GLP-1 use and altered bowel motility
*Attorneys handling these claims point to emergency imaging records and surgical operative notes as the documents that most clearly establish severity for intestinal obstruction cases.*
Bold callout: Intestinal obstruction cases requiring surgical intervention have historically settled at the upper range of pharmaceutical mass tort compensation grids, often $500,000 to $1.5 million in comparable litigation.
Ozempic Mass Tort vs. Class Action: Why the Distinction Matters for Your Payout
The Ozempic lawsuit is a mass tort, not a class action. That distinction directly affects how much individual claimants can receive.
In a class action, one settlement covers all plaintiffs equally. Everyone gets the same check regardless of how severe their injury was. In a mass tort, each plaintiff maintains an individual case. Settlement amounts reflect each claimant's specific damages, not an averaged figure spread across a large group.
MDL 3094 consolidates individual mass tort cases before one judge for pretrial efficiency. But each case retains its individual damages profile. A claimant with a feeding tube and permanent disability does not share a payout with someone who had a two-day hospitalization.
| Feature | Class Action | Mass Tort (MDL) |
|---|---|---|
| Individual cases retained | No | Yes |
| Equal payout for all | Yes | No |
| Individual damages considered | No | Yes |
| Bellwether trials used | Rarely | Standard practice |
| Payout range variance | Low | High |
*Attorneys handling these claims point to the mass tort structure as the reason claimants with documented severe injuries should prioritize complete medical record collection from the start of their case.*
Ozempic MDL 3094 Update 2026: Where the Case Stands
MDL 3094 in 2026 is in the active pretrial phase under Chief Judge Chad F. Kenney in the Eastern District of Pennsylvania.
The MDL was formally established by the Judicial Panel on Multidistrict Litigation on December 14, 2023. Since then, the case docket has grown to include over 12,000 federal complaints, with additional cases being filed monthly.
Key MDL 3094 developments through early 2026:
- Plaintiff Steering Committee (PSC) appointed and active
- Discovery disputes over Novo Nordisk internal clinical trial documents ongoing
- Case Management Orders governing electronic discovery and deposition protocol issued
- Short Form Complaints accepted for new claimants joining MDL
- Science Day held for Judge Kenney on GLP-1 pharmacology and gastroparesis causation
The most consequential pending event is the selection and scheduling of bellwether trial cases. The outcome of the first two to four bellwether trials will define the settlement grid for all remaining claimants.
*Attorneys handling these claims point to the internal Novo Nordisk document production as the litigation's most strategically important current battleground, because corporate knowledge of risk is central to both compensatory and punitive damages arguments.*
Litigation Watch: MDL 3094 is moving along a standard pharmaceutical mass tort timeline. Claimants who join early, before bellwether trials conclude, are positioned to benefit from the most favorable settlement dynamics.
Ozempic Bellwether Trial Schedule: What It Means for Settlement Timing
The Ozempic bellwether trial schedule is the most important variable determining when and at what value settlements will be reached across MDL 3094.
Bellwether trials are test cases. The court selects a small group of representative cases, tries them before juries, and observes the verdicts. Defense and plaintiff counsel then use those verdicts to calibrate realistic settlement values for the thousands of remaining cases. No MDL of this scale resolves without that process.
As of early 2026, bellwether pool selection is underway. Specific trial dates are subject to pretrial discovery completion, but the court's case management orders anticipate the first bellwether trials occurring in 2026 or early 2027.
Why bellwether outcomes matter to individual claimants:
- A high jury verdict signals defendants to settle remaining cases at elevated values
- A defense verdict suppresses the settlement market
- Most pharmaceutical MDLs settle before or shortly after the first two bellwether results
- Claimants not yet in the MDL may face reduced leverage if global resolution is announced before they file
*Attorneys handling these claims point to the Zofran MDL and the Invokana litigation as instructive precedents, where defendants began serious settlement talks after the first adverse bellwether result.*
Bold callout: In major pharmaceutical MDLs, the window between the first bellwether verdict and a global settlement announcement is often six to eighteen months. Claimants filing after a settlement is announced may receive lower individual allocations.
Ozempic Lawsuit Settlement Timeline: When Can Claimants Expect Payment?
The Ozempic lawsuit settlement timeline depends on when the first bellwether trials conclude and how quickly Novo Nordisk moves toward a global resolution.
Based on the MDL 3094 docket pace and comparison to pharmaceutical mass torts of similar scale, a projected timeline looks like this:
| Phase | Projected Timeframe |
|---|---|
| Bellwether pool selection complete | Mid-2026 |
| First bellwether trial(s) | Late 2026 to early 2027 |
| Settlement negotiations begin in earnest | 2027 |
| Global settlement fund announced | 2027 to 2028 |
| Claims administration and payment | 2028 to 2029 |
These projections are based on comparable MDL timelines. The Vioxx MDL resolved within four years of consolidation. The Invokana MDL took approximately three years from consolidation to settlement announcements.
No government agency has announced a settlement fund. Timelines can accelerate if Novo Nordisk determines trial exposure is too costly, or slow if discovery disputes extend the pretrial phase.
*Attorneys handling these claims point to the reality that individual claimants resolved early in pharmaceutical MDLs often receive payment before global fund distributions begin.*
Ozempic Lawsuit Filing Deadline 2026: Statute of Limitations Rules
The Ozempic lawsuit filing deadline in 2026 is not a single national date. It is determined by each state's statute of limitations for personal injury claims, and in most states that window is two to three years from the date of injury discovery.
The discovery rule governs when the clock starts. It begins when the claimant knew or reasonably should have known that their injury was caused by the drug. For many Ozempic patients, that date may be when a physician connected their gastroparesis diagnosis to their GLP-1 prescription.
Statute of limitations by selected states:
| State | Deadline for Personal Injury | Notes |
|---|---|---|
| California | 2 years from discovery | Discovery rule applies |
| Florida | 2 years (reduced from 4 in 2023) | Post-2023 cases use shorter window |
| Texas | 2 years from discovery | Strict application |
| New York | 3 years from injury | Extended for latent injuries |
| Pennsylvania | 2 years | Host state for MDL; same rule applies |
| Illinois | 2 years from discovery | |
| Ohio | 2 years |
Filing a complaint in federal court and joining MDL 3094 does not extend a state statute of limitations. Claimants whose state deadline is approaching must file before that date, regardless of the MDL's procedural status.
*Attorneys handling these claims point to statute of limitations expiration as the single most common reason otherwise valid claims are lost before they can be filed.*
Litigation Watch: Filing deadlines vary by state and are calculated from the date of injury discovery, not the date of diagnosis or drug recall. Claimants who believe they are within the window should verify their specific state deadline with a licensed attorney as a priority step.
How to File an Ozempic Lawsuit: The Process From Intake to MDL
Filing an Ozempic lawsuit means retaining a mass tort attorney, completing an intake evaluation, gathering medical records, and submitting a complaint that joins MDL 3094.
The process does not begin at the courthouse. It begins with a consultation with an attorney who handles pharmaceutical product liability claims. That attorney will evaluate whether the facts meet MDL eligibility requirements before any case is filed.
Step-by-step filing process:
- Initial consultation: Attorney reviews drug use history, injury history, and medical documentation
- Record gathering: Medical records, pharmacy records, and prescription history obtained
- Case evaluation: Attorney and medical team confirm causation linkage
- Complaint drafted: Short Form Complaint (SFC) prepared consistent with MDL requirements
- Federal filing: Complaint filed in any federal district court; JPML automatically transfers case to Eastern District of Pennsylvania
- Entry into MDL docket: Case assigned docket number within MDL 3094
- Discovery participation: Plaintiff responds to Master Discovery requests coordinated by PSC
Total time from intake to MDL entry typically runs four to eight weeks with complete documentation.
*Attorneys handling these claims point to pharmacy records as the most overlooked document, since claimants sometimes have prescriptions filled at multiple pharmacies and incomplete fill histories can complicate causation arguments.*
Ozempic Lawsuit Novo Nordisk: The Defendant's Legal Position
Novo Nordisk is the Danish pharmaceutical manufacturer defending MDL 3094 and the largest defendant in this litigation.
The company markets Ozempic (semaglutide 0.5mg, 1mg, and 2mg) for Type 2 diabetes management and Wegovy (semaglutide 2.4mg) for chronic weight management. Both products contain the same active compound at different dosing levels.
Novo Nordisk's public legal posture emphasizes that semaglutide products are approved by the FDA, that the drugs carry appropriate labeling, and that the gastrointestinal side effects named in lawsuits are documented in prescribing information. Defense filings in MDL 3094 argue that gastroparesis has multiple causes and that plaintiffs face a difficult specific causation burden.
Novo Nordisk's primary defense arguments:
- Ozempic and Wegovy are FDA-approved with appropriate risk disclosure
- Gastroparesis is a known complication of Type 2 diabetes itself, independent of drug use
- Plaintiff populations frequently have pre-existing conditions that could independently cause GI injury
- No definitive clinical study establishes a causal link between semaglutide and permanent gastroparesis
*Attorneys handling these claims point to Novo Nordisk's internal clinical trial communications as the documentary area most likely to undermine the "adequate warning" defense if those documents show earlier knowledge of serious GI risk.*
Bold callout: Novo Nordisk reported global net sales of approximately $33.7 billion in 2023, driven largely by Ozempic and Wegovy. The company has substantial resources to contest the litigation, which typically extends the timeline before global settlement discussions begin.
Ozempic Lawsuit States Where Cases Are Filed: Geographic Distribution
Ozempic lawsuit cases are filed in federal courts across all fifty states, with concentration in states with the largest Ozempic prescription populations.
Because the cases consolidate into MDL 3094 in the Eastern District of Pennsylvania regardless of where they are originally filed, geography affects the statute of limitations and certain damages calculations rather than the forum where the case is ultimately managed.
States with highest reported Ozempic prescription volumes and corresponding claim concentrations:
| State | Notes |
|---|---|
| California | Largest prescription market nationally |
| Texas | High diabetes prevalence, large claimant pool |
| Florida | Large elderly population, high Type 2 diabetes rates |
| New York | Urban concentration of plaintiffs |
| Pennsylvania | Host state for MDL; active plaintiff bar |
| Illinois | Major Midwest filing center |
| Ohio | Significant manufacturing and healthcare employment population |
State law still governs damages caps, consortium claims, and certain procedural elements even within the federal MDL. A Texas plaintiff with a damages cap concern and a New York plaintiff operating under a different damages framework will have different case value calculations even with identical injuries.
*Attorneys handling these claims point to the interplay between state damages law and MDL federal procedure as one of the most consistently misunderstood aspects of pharmaceutical mass tort litigation for claimants.*
Ozempic Lawsuit Lawyer: What Type of Attorney Handles These Claims
The Ozempic lawsuit requires a mass tort or pharmaceutical product liability attorney, not a general personal injury lawyer.
Mass tort litigation is a subspecialty. Attorneys who handle these cases maintain relationships with medical experts, operate efficiently within MDL Case Management Orders, and understand the Plaintiff Steering Committee structure. A general personal injury attorney who handles car accidents and slip-and-fall cases is not equipped to litigate pharmaceutical product liability at the federal MDL level.
What to look for in an Ozempic lawsuit attorney:
- Documented experience in pharmaceutical mass torts or MDL litigation
- Membership in or affiliation with the MDL 3094 Plaintiff Steering Committee or co-counsel relationships with PSC firms
- Ability to access and coordinate medical expert review for causation analysis
- Contingency fee representation (claimants pay no upfront legal fees; attorney takes a percentage if successful)
- State licensure in the claimant's home state plus federal bar admission
Questions to ask at a consultation:
- How many pharmaceutical MDL cases have you handled?
- Are you affiliated with the MDL 3094 Plaintiff Steering Committee?
- What is your contingency fee percentage?
- How will you gather and evaluate my medical records?
- What injury tier do you believe my case falls into?
*Attorneys handling these claims point to contingency fee structures as the reason claimants face no financial barrier to entry, since reputable mass tort firms only collect fees upon a successful resolution.*
Bold callout: Contingency fees in pharmaceutical mass torts typically range from 33% to 40% of gross recovery. A written fee agreement before signing a retainer is not optional. It is standard practice.
Frequently Asked Questions
What are the current Ozempic lawsuit settlement amounts in 2026?
No global settlement fund has been announced as of early 2026.
Projected individual settlement ranges are $75,000 to $1.5 million or more, depending on injury severity and documentation.
Wrongful death claims may exceed $3 million in some projections.
Who qualifies to file an Ozempic lawsuit?
Patients who took Ozempic, Wegovy, or another semaglutide drug and were subsequently diagnosed with gastroparesis, intestinal obstruction, or a related gastrointestinal condition qualify for screening.
Medical records confirming the diagnosis and showing the drug was prescribed are required.
Pre-existing gastroparesis before drug use began will likely disqualify a claim.
How long does it take to receive an Ozempic lawsuit settlement?
Based on comparable pharmaceutical mass torts, most claimants should not expect payment before 2027 to 2028 at the earliest.
Bellwether trials must conclude before global settlement negotiations produce a fund formula.
Individual early resolutions outside the global fund can happen sooner.
What injuries qualify for the Ozempic lawsuit?
Qualifying injuries include gastroparesis, gastric motility disorder, intestinal obstruction, ileus, aspiration pneumonia secondary to gastroparesis, bezoar formation, and severe dehydration or malnutrition caused by persistent vomiting.
Nausea or vomiting without a physician-confirmed underlying diagnosis is generally insufficient.
All qualifying injuries must be documented in medical records with a clear chronological link to drug use.
Is the Ozempic lawsuit a class action or a mass tort?
The Ozempic litigation is a mass tort consolidated under MDL 3094, not a class action.
Each claimant retains an individual case with individual damages.
Payouts vary based on each person's injury severity rather than being equally distributed across all plaintiffs.
What type of lawyer handles Ozempic lawsuits?
Pharmaceutical product liability attorneys and mass tort litigation specialists handle Ozempic claims.
These attorneys operate on contingency, meaning no upfront cost to the claimant.
Affiliation with the MDL 3094 Plaintiff Steering Committee or a formal co-counsel relationship with a PSC firm is an indicator of relevant MDL experience.
What Claimants Should Do Now
MDL 3094 is active and growing. The window before bellwether trials conclude, and before the settlement negotiation dynamic changes, is the most strategically favorable period for claimants to enter the litigation.
Statute of limitations deadlines are real and jurisdiction-specific. A claim that is factually strong can be permanently barred if the applicable state deadline passes before a complaint is filed.
Claimants who took Ozempic, Wegovy, or Rybelsus and received a diagnosis of gastroparesis, intestinal obstruction, or a related condition should consult with a pharmaceutical mass tort attorney. That consultation costs nothing under a contingency arrangement and provides a clear picture of where a specific case stands within the MDL 3094 framework.
